Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13772-13789

  Raimondi, Lavinia ^a   De Luca, Angela ^a   Amodio, Nicola ^b   Manno, Mauro ^c   Raccosta, Samuele ^c   Taverna, Simona ^d   Bellavia, Daniele ^a   Naselli, Flores ^d   Fontana, Simona ^d   Schillaci, Odessa ^d   Giardino, Roberto ^a   Fini, Milena ^a   Tassone, Pierfrancesco ^b   Santoro, Alessandra ^e   De Leo, Giacomo ^d   Giavaresi, Gianluca ^a   Alessandro, Riccardo ^d,f  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e AO Ospedali Riuniti Villa Sofia Cervello   (Italy)

^f CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Exosomes; Multiple myeloma; Osteoclasts; Tumor microenvironment

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; CHEMOKINE RECEPTOR CXCR4; GELATINASE B;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; INTERNALIZATION; MACROPHAGE; MOUSE; MULTINUCLEAR CELL; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; ANIMAL; CONFOCAL MICROSCOPY; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAW 264.7 CELL LINE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; CELL DIFFERENTIATION; EXOSOMES; HUMANS; MICE; MICROSCOPY, CONFOCAL; MULTIPLE MYELOMA; OSTEOCLASTS; RAW 264.7 CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84931032854     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3830     Document Type: Article

References (63)

1. Raje N and Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011; 17:1278-1286.
2. Hameed A, Brady JJ, Dowling P, Clynes M and O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis. 2014; 7:33-42.
3. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, Misso G, Tassone P and Caraglia M. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets. 2012; 12:757-767.
4. Sebag M. CCR1 blockade and myeloma bone disease. Blood. 2012; 120:1351-1352.
5. Terpos E, Moulopoulos LA and Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol. 2011; 29:1907-1915.
6. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gulla A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012; 18:6260-6270.
7. Ghobrial IM. Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new? Leuk Lymphoma. 2013; 54:2328-2330.
8. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, Botta C, Paolino FM, Del Giudice T, Iuliano E, Caraglia M, Ferrarini M, Giordano A, Tagliaferri P and Tassone P. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2013; 228:1506-1515.
9. Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C and Sezer O. Bone markers in multiple myeloma. Eur J Cancer. 2006; 42:1544-1553.
10. Silbermann R, Bolzoni M, Storti P, Guasco D, Bonomini S, Zhou D, Wu J, Anderson JL, Windle JJ, Aversa F, David Roodman G and Giuliani N. Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia. 2014; 28:951-954.
11. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D and Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004; 104:2484-2491.
12. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B and Shaughnessy JD, Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349:2483-2494.
13. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999; 96:3540-3545.
14. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J and Choi Y. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001; 98:11581-11586.
15. Giuliani N, Bataille R, Mancini C, Lazzaretti M and Barille S. Myeloma cells induce imbalance in the osteoprotegerin/ osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001; 98:3527-3533.
16. Kim N, Odgren PR, Kim DK, Marks SC, Jr. and Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A. 2000; 97:10905-10910.
17. Peinado H, Lavotshkin S and Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011; 21:139-146.
18. Corrado C, Raimondo S, Chiesi A, Ciccia F, De Leo G and Alessandro R. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci. 2013; 14:5338-5366.
19. Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami M, Huber V, Maio M, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009; 4:e5219.
20. O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW and O'Driscoll L. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer. 2013; 49:1845-1859.
21. Kahlert C and Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). 2013; 91:431-437.
22. Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K and Menu E. Bone marrow stromal cellderived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014; 124:555-566.
23. Arendt BK, Walters DK, Wu X, Tschumper RC and Jelinek DF. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget. 2014; 5:5686-5699.
24. Savina A, Vidal M and Colombo MI. The exosome pathway in K562 cells is regulated by Rab11. J Cell Sci. 2002; 115:2505-2515.
25. Szymczyk KH, Freeman TA, Adams CS, Srinivas V and Steinbeck MJ. Active caspase-3 is required for osteoclast differentiation. J Cell Physiol. 2006; 209:836-844.
26. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B and Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004; 64:2016-2023.
27. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004; 32:290-292.
28. Noto R, Santangelo MG, Ricagno S, Mangione MR, Levantino M, Pezzullo M, Martorana V, Cupane A, Bolognesi M and Manno M. The tempered polymerization of human neuroserpin. PLoS One. 2012; 7:e32444.
29. Escrevente C, Keller S, Altevogt P and Costa J. Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer. 2011; 11:108.
30. Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ, Chang LF, Zhou Q and Sui SF. Cellular internalization of exosomes occurs through phagocytosis. Traffic. 2010; 11:675-687.
31. Liu Y, Zhu XJ, Zeng C, Wu PH, Wang HX, Chen ZC and Li QB. Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin. 2014; 35:230-238.
32. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W and Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001; 276:20659-20672.
33. Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term followup. J Clin Oncol. 2011; 29:3016-3022.
34. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC and Anderson KC. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007; 21:1007-1034, vii-viii.
35. Basak GW, Srivastava AS, Malhotra R and Carrier E. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol. 2009; 10:345-346.
36. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT and Ghobrial IM. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013; 123:1542-1555.
37. Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K and Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014; 124:3748-3757.
38. Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, Caracciolo D, Gulla A, Neri A, Taverna S, D'Aquila P, Alessandro R, Giordano A, Tagliaferri P and Tassone P. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget. 2014; 5:3039-3054.
39. Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maiga S, Franceschi V, Colla S, Anderson J, Neri A, et al. Hypoxia-inducible factor (HIF)-1 alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 2013; 27:1697-1706.
40. Amodio N, Di Martino MT, Neri A, Tagliaferri P and Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 2013; 13 Suppl 1:S125-137.
41. Leotta M, Biamonte L, Raimondi L, Ronchetti D, Di Martino MT, Botta C, Leone E, Pitari MR, Neri A, Giordano A, Tagliaferri P, Tassone P and Amodio N. A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells. Journal of Cellular Physiology. 2014; 229:2106-2116.
42. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, Fabiani F, Leone E, Gulla AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P and Tassone P. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget. 2012; 3:1246-1258.
43. Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P, Di Martino MT, Calimeri T, Rossi M, Lionetti M, Leone E, Passarino G, Neri A, Giordano A, Tagliaferri P and Tassone P. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013; 12:3650-3662.
44. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A and Tassone P. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets. 2012; 12:838-846.
45. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y and Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002; 116:278-290.
46. Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P and Osdoby P. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone. 2005; 36:840-853.
47. de Mel S, Lim SH, Tung ML and Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int. 2014; 2014:232546.
48. Aimes RT and Quigley JP. Matrix metalloproteinase-2 is an interstitial collagena. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem. 1995; 270:5872-5876.
49. Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K and Suda T. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria:association of MMP induction with bone resorption. Endocrinology. 1998; 139:1338-1345.
50. Costa AG, Cusano NE, Silva BC, Cremers S and Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011; 7:447-456.
51. Giuliani N, Rizzoli V and Roodman GD. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood. 2006; 108:3992-3996.
52. Rafiei S and Komarova SV. Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells. BMC Cancer. 2013; 13:605.
53. Teitelbaum SL. The osteoclast and its unique cytoskeleton. Ann N Y Acad Sci. 2011; 1240:14-17.
54. Chambers TJ and Fuller K. How are osteoclasts induced to resorb bone? Ann N Y Acad Sci. 2011; 1240:1-6.
55. Teitelbaum SL. Bone resorption by osteoclasts Science. 2000; 289(5484):1504-1508.
56. Bharti AC and Aggarwal BB. Ranking the role of RANK ligand in apoptosis. Apoptosis. 2004; 9:677-690.
57. Xing L, Schwarz EM and Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev. 2005; 208:19-29.
58. Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM, Jr., Paulaitis ME, Freitas MA and Pichiorri F. Characterization of multiple myeloma vesicles by label-free relative quantitation. Proteomics. 2013; 13:3013-3029.
59. Cai D, Cao J, Li Z, Zheng X, Yao Y, Li W and Yuan Z. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer. 2009; 9:102.
60. Taverna S, Flugy A, Saieva L, Kohn EC, Santoro A, Meraviglia S, De Leo G and Alessandro R. Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer. 2012; 130:2033-2043.
61. Thery C, Amigorena S, Raposo G and Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; Chapter 3:Unit 3 22.
62. Corrado C, Raimondo S, Saieva L, Flugy AM, De Leo G and Alessandro R. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer Lett. 2014; 348:71-76.
63. Taverna S, Amodeo V, Saieva L, Russo A, Giallombardo M, De Leo G and Alessandro R. Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells. Mol Cancer. 2014; 13:169.